BARD1 Life Sciences Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume801,545 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive BD1 News and Ratings via Email

Sign-up to receive the latest news and ratings for BARD1 Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

About BARD1 Life Sciences

BARD1 Life Sciences Limited engages in the research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer to enhance patient outcomes and save lives in Australia. Its cancer diagnostics portfolio includes commercialized hTERT test used as an adjunct to urine cytology testing; and diagnostic tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The company is also providing Molecular NET technology, including its EXO-NETTM product to capture and purify exosomes. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BARD1 Life Sciences (ASX:BD1) Frequently Asked Questions

What stocks does MarketBeat like better than BARD1 Life Sciences?

Wall Street analysts have given BARD1 Life Sciences a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BARD1 Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are BARD1 Life Sciences' key executives?

BARD1 Life Sciences' management team includes the following people:
  • Dr. Leearne Maree Hinch BSc., B.V.M.S., M.R.C.V.S., M.B.A., Chief Exec. Officer
  • Mr. Peter Lynton Gunzburg B Comm, ASIA, Managing Director (Age 69, Pay $82.12k)
  • Mr. Tony Di Pietro AGIA, C.A., M.A.I.C.D., B.Com, CPA, CFO & Joint Company Sec.
  • Mr. Carl S. Stubbings, Chief Operating Officer
  • Dr. Peter William French M.B.A., B.Sc., M.Sc., Ph.D., MBA, FRSM, Chief Scientific Officer
  • Ms. Pauline Anne Collinson, Joint Company Sec. (Age 65)

Who are some of BARD1 Life Sciences' key competitors?

What is BARD1 Life Sciences' stock symbol?

BARD1 Life Sciences trades on the ASX under the ticker symbol "BD1."

How much money does BARD1 Life Sciences make?

BARD1 Life Sciences has a market capitalization of $0.00 and generates $612,251.00 in revenue each year.

How many employees does BARD1 Life Sciences have?

BARD1 Life Sciences employs 5 workers across the globe.

What is BARD1 Life Sciences' official website?

The official website for BARD1 Life Sciences is

How can I contact BARD1 Life Sciences?

The company can be reached via phone at 61 8 9381 9550.

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.